On February 13th, Japan Tobacco Inc. (JTI) released its financial report for the year 2024. The report showed that sales revenue for 2024 reached 3.15 trillion Japanese yen (approximately 20.5 billion US dollars), representing a year-on-year increase of 10.9%. Operating profit was 697.2 billion yen (approximately 4.5 billion US dollars), a year-on-year increase of 3.7%, while net profit attributable to the company's owners was 463.4 billion yen (approximately 3 billion US dollars), a year-on-year decrease of 3.9%.
A report shows that Japan Tobacco is gradually expanding its diversified business layout, with tobacco remaining the core revenue driver contributing a revenue of 2.78 trillion yen (approximately $18 billion). The growth mainly comes from the Asian, European, and Middle East/Africa (EMA) markets, indicating that Japan Tobacco continues to maintain competitiveness in the global tobacco market.
The sales of the pharmaceutical business slightly declined to 94.4 billion yen (approximately 0.62 billion US dollars). The report attributed this decrease primarily to intensified market competition. On the other hand, the food business showed growth momentum, with sales reaching 157.2 billion yen (approximately 1 billion US dollars), contributing to the diversification of the group's revenue.
Japan Tobacco Inc. has forecasted its performance for the year 2025, expecting sales revenue to continue growing by 3.9% to reach 3.27 trillion yen (approximately 21.2 billion US dollars). Adjusted operating profit is projected to decrease by 2.2% to 735 billion yen (about 4.8 billion US dollars). Net profit attributable to owners of the parent company is expected to drop by 2.9% to 450 billion yen (around 3 billion US dollars).
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
